2020 Pipeline Insight on Allergic Rhinitis - ResearchAndMarkets.com
The "Allergic Rhinitis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Allergic Rhinitis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present clinical development scenario and growth prospects across the allergic rhinitis market. A detailed picture of the allergic rhinitis pipeline landscape is provided, which includes the disease overview and allergic rhinitis treatment guidelines.
The assessment part of the report embraces in-depth allergic rhinitis commercial assessment and clinical assessment of the allergic rhinitis pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, allergic rhinitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Report highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for allergic rhinitis.
- In the coming years, the allergic rhinitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence allergic rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the allergic rhinitis treatment market. several potential therapies for allergic rhinitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the allergic rhinitis market size in the coming years.
-
In-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of allergic rhinitis ) includes therapeutic assessment and comparative analysis.
Key questions
- How many therapies are developed by each company for the treatment of allergic rhinitis?
- How many allergic rhinitis emerging therapies are in early-stage, mid-stage, and late stages of development for the treatment of allergic rhinitis?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and major licensing activities that will impact the allergic rhinitis market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of allergic rhinitis?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing allergic rhinitis therapies?
- What are the clinical studies going on for allergic rhinitis and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for allergic rhinitis?
-
How many patents are granted and pending for the emerging therapies for the treatment of allergic rhinitis?
Key Topics Covered:
1. Report Introduction
2. Allergic Rhinitis
2.1. Overview
2.2. History
2.3. Allergic Rhinitis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Allergic Rhinitis Diagnosis
2.6.1. Diagnostic Guidelines
3. Allergic Rhinitis Current Treatment Patterns
3.1. Allergic Rhinitis Treatment Guidelines
4. Allergic Rhinitis - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Allergic Rhinitis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Allergic Rhinitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Allergic Rhinitis Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Allergic Rhinitis Late Stage Products (Phase-III)
7. Allergic Rhinitis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Allergic Rhinitis Discontinued Products
13. Allergic Rhinitis Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Allergic Rhinitis Key Companies
15. Allergic Rhinitis Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Allergic Rhinitis Unmet Needs
18. Allergic Rhinitis Future Perspectives
19. Allergic Rhinitis Analyst Review
20. Appendix
21. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/i3ul4m
View source version on businesswire.com: https://www.businesswire.com/news/home/20200217005192/en/